Toby Maurer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Toby Maurer has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Kieron S. Leslie
Department of Dermatology, UCSF School of Medicine, 1701 Divisadero Street, 3rd Floor, San Francisco, CA 94115, USA
2 shared publicationsPatrick Unemori
Department of Dermatology, UCSF School of Medicine, 1701 Divisadero Street, 3rd Floor, San Francisco, CA 94115, USA
2 shared publicationsA.L. Isenstein
School of Medicine and Department of Dermatology, University of California San Francisco, San Francisco General Hospital, San Francisco, CA 94110, U.S.A. Correspondence: Toby Maurer
1 shared publication- Audrey L. French
B Ruth M. Rothstein CORE Center, Cook County Health and Hospitals System , Chicago , IL , USA
1 shared publication - Chenglong Liu
A Department of Medicine , Georgetown University , Washington , USA
1 shared publication - Cuiwei Wang
A Department of Medicine , Georgetown University , Washington , USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 10 (1) , 34
Effects of highly active antiretroviral therapy and its adherence on herpes zoster incidence: a longitudinal cohort study
Herpes zoster (HZ) is common among HIV-infected individuals, but the impacts of highly active antiretroviral therapy (HAART) and HAART adherence on HZ risk have not been well studied.
- 1 January 2013
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 10 (1) , 34
Open AccessEffects of highly active antiretroviral therapy and its adherence on herpes zoster incidence: a longitudinal cohort study
Herpes zoster (HZ) is common among HIV-infected individuals, but the impacts of highly active antiretroviral therapy (HAART) and HAART adherence on HZ risk have not been well studied.
- Open Access
- 1 January 2013
- Published by Wiley in Dermatology Research and Practice
- Vol. 2013, 1-3
Cutis Verticis Gyrata in Men Affected by HIV-Related Lipodystrophy
We report the occurrence of cutis verticis gyrata (CVG), a disfiguring dermatological condition, in four patients with HIV-related lipodystrophy (HIVLD). These four patients had abnormal metabolic and hormonal lab values which we compare with metabolic and hormonal perturbations cited in previous HIVLD cohorts. In addition, we describe the sole use of poly-L-lactic acid as a potential treatment for decreasing the appearance of CVG-associated ridges.
- 1 January 2013
- Published by Wiley in Dermatology Research and Practice
- Vol. 2013, 1-3
Open AccessCutis Verticis Gyrata in Men Affected by HIV-Related Lipodystrophy
We report the occurrence of cutis verticis gyrata (CVG), a disfiguring dermatological condition, in four patients with HIV-related lipodystrophy (HIVLD). These four patients had abnormal metabolic and hormonal lab values which we compare with metabolic and hormonal perturbations cited in previous HIVLD cohorts. In addition, we describe the sole use of poly-L-lactic acid as a potential treatment for decreasing the appearance of CVG-associated ridges.
- 1 August 2009
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 61 (2) , 345-347
Disseminated herpes zoster with increased CD4 counts in 3 HIV-infected patients
- 1 August 2009
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 61 (2) , 345-347
Disseminated herpes zoster with increased CD4 counts in 3 HIV-infected patients
- 1 July 2008
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 3 (4) , 453-460
Cutaneous manifestations of immune reconstitution inflammatory syndrome
Purpose of review The introduction of highly active antiretroviral therapy (HAART) has altered the pattern of dermatologic disease among HIV-infected patients. While the majority benefit substantially from highly active antiretroviral therapy-induced immune recovery, a subset of patients experience unmasking of new skin disease or paradoxical worsening of existing dermatologic conditions, attributable to immune reconstitution inflammatory syndrome. We review the current literature regarding the dermatologic manifestations of immune reconstitution inflammatory syndrome. Recent findings Cutaneous immune reconstitution inflammatory syndrome is described in association with a range of infectious, inflammatory, neoplastic, and autoimmune disorders. The list of skin manifestations of immune reconstitution inflammatory syndrome continues to grow, with current literature highlighting the emergence of tropical skin diseases, such as leishmaniasis and leprosy, presenting in the context of immune recovery. Increasingly, we are recognizing common skin eruptions such as acne may be associated with immune reconstitution inflammatory syndrome. There are also recent descriptions of previously unreported presentations of well established immune reconstitution inflammatory syndrome-related conditions. These include Mycobacterium avium presenting as cutaneous ulceration and an epidermodysplasia verruciformis-like eruption of warts. Additionally, authors are attempting to define the unique immunopathology associated with immune reconstitution inflammatory syndrome in the context of specific cutaneous diseases. Summary Optimal management depends on recognition of immune reconstitution inflammatory syndrome as a unique syndrome by healthcare providers, rather than a failure of highly active antiretroviral therapy or an adverse drug reaction. Our understanding of dermatologic immune reconstitution inflammatory syndrome continues to evolve as the diversity of reported cutaneous immune reconstitution inflammatory syndrome-associated disorders expands.
- 1 July 2008
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 3 (4) , 453-460
Cutaneous manifestations of immune reconstitution inflammatory syndrome
Purpose of review The introduction of highly active antiretroviral therapy (HAART) has altered the pattern of dermatologic disease among HIV-infected patients. While the majority benefit substantially from highly active antiretroviral therapy-induced immune recovery, a subset of patients experience unmasking of new skin disease or paradoxical worsening of existing dermatologic conditions, attributable to immune reconstitution inflammatory syndrome. We review the current literature regarding the dermatologic manifestations of immune reconstitution inflammatory syndrome. Recent findings Cutaneous immune reconstitution inflammatory syndrome is described in association with a range of infectious, inflammatory, neoplastic, and autoimmune disorders. The list of skin manifestations of immune reconstitution inflammatory syndrome continues to grow, with current literature highlighting the emergence of tropical skin diseases, such as leishmaniasis and leprosy, presenting in the context of immune recovery. Increasingly, we are recognizing common skin eruptions such as acne may be associated with immune reconstitution inflammatory syndrome. There are also recent descriptions of previously unreported presentations of well established immune reconstitution inflammatory syndrome-related conditions. These include Mycobacterium avium presenting as cutaneous ulceration and an epidermodysplasia verruciformis-like eruption of warts. Additionally, authors are attempting to define the unique immunopathology associated with immune reconstitution inflammatory syndrome in the context of specific cutaneous diseases. Summary Optimal management depends on recognition of immune reconstitution inflammatory syndrome as a unique syndrome by healthcare providers, rather than a failure of highly active antiretroviral therapy or an adverse drug reaction. Our understanding of dermatologic immune reconstitution inflammatory syndrome continues to evolve as the diversity of reported cutaneous immune reconstitution inflammatory syndrome-associated disorders expands.
- 27 September 2007
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (13) , 1352-1353
HIV-Associated Kaposi's Sarcoma with a High CD4 Count and a Low Viral Load
Kaposi's sarcoma associated with HIV infection has been decreasing in incidence and severity since the introduction of antiretroviral therapy.1 These reductions have been attributed to improved immune function directly related to such therapy. Patients with Kaposi's sarcoma typically have a low CD4 cell count (10,000 copies per milliliter).1,2 In the majority of patients, the regression of Kaposi's sarcoma lesions has been reported to occur within 8 months after the initiation of antiretroviral therapy, paralleling the increase in the CD4 cell count and decrease in the viral load that mark successful therapy.3 Likewise, progression of Kaposi's sarcoma has been associated with a high viral load, a low CD4 cell count, and concomitant opportunistic infections.2,3
- 27 September 2007
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (13) , 1352-1353
HIV-Associated Kaposi's Sarcoma with a High CD4 Count and a Low Viral Load
Kaposi's sarcoma associated with HIV infection has been decreasing in incidence and severity since the introduction of antiretroviral therapy.1 These reductions have been attributed to improved immune function directly related to such therapy. Patients with Kaposi's sarcoma typically have a low CD4 cell count (10,000 copies per milliliter).1,2 In the majority of patients, the regression of Kaposi's sarcoma lesions has been reported to occur within 8 months after the initiation of antiretroviral therapy, paralleling the increase in the CD4 cell count and decrease in the viral load that mark successful therapy.3 Likewise, progression of Kaposi's sarcoma has been associated with a high viral load, a low CD4 cell count, and concomitant opportunistic infections.2,3
- 25 April 2006
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 155 (1) , 227-228
Vaginal bleeding after initiation of isotretinoin in a female-to-male transsexual on testosterone
- 25 April 2006
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 155 (1) , 227-228
Vaginal bleeding after initiation of isotretinoin in a female-to-male transsexual on testosterone